Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt